These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3552347)

  • 21. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
    Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
    Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C
    Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review.
    Pedersen-Bjergaard J
    Leuk Res; 1992; 16(1):61-5. PubMed ID: 1732675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complex cytogenetics in a case of probably work related MDS/AML.
    Salamanchuk Z; Jakóbczyk M; Nowak W; Skotnicki AB
    Leuk Res; 2004 Dec; 28(12):1357-61. PubMed ID: 15475079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.
    Kantarjian HM; Keating MJ; Walters RS; Smith TL; Cork A; McCredie KB; Freireich EJ
    J Clin Oncol; 1986 Dec; 4(12):1748-57. PubMed ID: 3783201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
    Le Beau MM; Albain KS; Larson RA; Vardiman JW; Davis EM; Blough RR; Golomb HM; Rowley JD
    J Clin Oncol; 1986 Mar; 4(3):325-45. PubMed ID: 3950675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents.
    Bennett JM; Moloney WC; Greene MH; Boice JD
    Hematol Pathol; 1987; 1(2):99-104. PubMed ID: 3504435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia after therapy with alkylating agents for childhood cancer.
    Tucker MA; Meadows AT; Boice JD; Stovall M; Oberlin O; Stone BJ; Birch J; Voûte PA; Hoover RN; Fraumeni JF
    J Natl Cancer Inst; 1987 Mar; 78(3):459-64. PubMed ID: 3469460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
    Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
    Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.